FDA Hits Indoco on Quality Control, Responses to 1,500 Complaints
The FDA cited an Indoco Remedies API facility in Goa, India, for serious quality failures and inadequate handling of complaints.
Indoco received approximately 1,500 complaints between 2012 and 2016 that its sterile solution bottles were leaking, empty or underfilled, the FDA said in a warning letter following an inspection of the facility in late August and early September 2016.
The agency found the defects were likely the result of improper bottle placement during filling, leading to cracks. Despite a company evaluation deeming the defects “high severity,” the company classed fixing the problem as a “moderate” priority.
The company said it has taken corrective actions since 2013, but it has continued to receive many complaints.
The FDA called on Indoco to provide a detailed risk assessment and to investigate whether its other products have similar quality issues.
The way drug and biologics concerns report quality metrics data to the FDA is about to change for good. A regulation nearing finalization will affect every company large and small that manufactures, prepares, propagates or compounds active ingredients or pharmaceutical products produced and sold in the U.S. The final reg will be out before you know it. Seize this opportunity to get an advance look from people who know what they’re talking about. Get ahead and order your webinar CD/Transcript copy of Submission of Quality Metrics Data today.